NIH Blueprint for Neuroscience Research Grand Challenge: Developing Novel Drugs for Disorders of the Nervous System (U01)
Closed Posted
- Opportunity number
- RFA-NS-12-002
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
-
- 93.113 Environmental Health
- 93.121 Oral Diseases and Disorders Research
- 93.173 Research Related to Deafness and Communication Disorders
- 93.213 Research and Training in Complementary and Integrative Health
- 93.242 Mental Health Research Grants
- 93.273 Alcohol Research Programs
- 93.279 Drug Use and Addiction Research Programs
- 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health
- 93.361 Nursing Research
- 93.389 National Center for Research Resources
- Funding instrument
- Cooperative Agreement
- Categories
-
- Education
- Environment
- Health
- Income Security and Social Services
- Eligible applicants
-
- Public or Indian Housing Auth.
- Small Businesses
- County Governments
- 501(c)(3) Nonprofits
- Tribal Governments (Federally Recognized)
- Independent School Districts
- Higher Education Inst. (Private)
- For Profit Organizations
- State Governments
- Special District Governments
- Higher Education Inst. (Public)
- Other
- City/Township Governments
- Non-501(c)(3) Nonprofits
- Tribal Organizations (Not Federally Recognized)
- Full announcement
Opportunity details come from Grants.gov. Updated .
Synopsis
The National Institutes of Health (NIH) announces a unique opportunity for investigators working with small molecule compounds to gain access to a robust virtual pharma drug development network to develop neurotherapeutic drugs. Successful applicants to this FOA will become collaborative participants in this network, receiving both funding and no-cost access to contracted drug development services that are not typically available to the academic research community. Funding will be provided through a U01 cooperative agreement mechanism to conduct biological testing of compound analogs in disease assays and models in the investigators laboratory. No-cost drug development services will also be provided, including medicinal chemistry optimization, IND-directed pharmacology and toxicology, and Phase I clinical testing. Researchers in possession of disease assays and small molecule compounds that show promise for treating nervous system and psychiatric disorders, but that are not yet suitable for clinical testing, are strongly encouraged to apply.
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign (non-U.S.) components of U.S. Organizations are allowed.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity